Published date: 1 March 2022

This notice was replaced on 15 July 2022

This notice does not contain the most up-to-date information about this procurement. The most recent notice is:

Awarded contract (published 8 August 2023)

Awarded contract - This means that the contract has been awarded to a supplier.


Contract summary

Industry

  • Pharmaceutical products - 33600000

Location of contract

WA7 2ES

Value of contract

£431,836,170

Procurement reference

CF-0634100D0O000000rwimUAA1

Published date

1 March 2022

Closing date

20 October 2021

Closing time

1pm

Contract start date

1 March 2022

Contract end date

29 February 2024

Contract type

Supply contract

Procedure type

Open procedure (above threshold)

Any interested supplier may submit a tender in response to an opportunity notice.

This procedure can be used for procurements above the relevant contract value threshold.

Contract is suitable for SMEs?

Yes

Contract is suitable for VCSEs?

No

Description

Offer reference number: CM/PHR/20/5600
CM/PHR/20/5600/01 - NHS Framework for the North of England, Branded Medicines -Tranche B - 1 March 2022 to 29 February 2024 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months
CM/PHR/20/5600/02 - NHS Framework for the North of England, Branded Medicines - Annual Tranche Products. Period of framework: 1 March 2022 to 28 February 2023 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 12 months.
CM/PHR/20/5600/03- NHS Framework for Insulin Aspart Biosimilar (Trurapi®), South of England - Period of framework: 1 March 2022 to 31 August 2022 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 12 months.
CM/PHR/20/5600/04 - NHS Framework for Insulin Aspart Biosimilar (Trurapi®), London - Period of framework: 1 March 2022 to 31 August 2023 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months.
CM/PHR/20/5600/05 - NHS Framework for Insulin Aspart Biosimilar (Trurapi®), Midlands and East - Period of framework: 1 March 2022 to 28 February 2023 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months.

Award information

Awarded date

7 February 2022

Contract start date

1 March 2022

Contract end date

29 February 2024

Total value of contract

£238,913,892

This contract was awarded to 31 suppliers.

Thornton and Ross Ltd

Address

, Huddersfield

Reference

None

Janssen-Cilag Ltd

Address

, High Wycombe

Reference

None

Biogen

Address

, Maidenhead

Reference

None

Merck Serono Limited

Address

, Feltham

Reference

None

Celltrion Healthcare United Kingdom Limited

Address

, Slough

Reference

None

Bristol Myers Squibb

Address

, Uxbridge

Reference

None

AstraZeneca

Address

, Luton

Reference

None

UL Global Pharma

Address

, Hertfordshire

Reference

None

Supplier is SME?

Yes

GlaxoSmithKline UK Limited

Address

, London

Reference

None

Roche Products Ltd

Address

, Garden City

Reference

None

Bayer Ltd

Address

, Reading

Reference

None

Merck Sharpe & Dohme (UK) Limited

Address

, London

Reference

None

Pfizer Ltd

Address

, Kent

Reference

None

Accord-UK Ltd

Address

, Devon

Reference

None

Novo Nordisk

Address

, Gatwick

Reference

None

Sandoz Ltd

Address

, Camberley

Reference

None

Supplier is SME?

Yes

Napp Pharmaceuticals Ltd

Address

, Cambridge

Reference

None

Eli Lilly & Company Ltd

Address

, Basingstoke

Reference

None

Ipsen

Address

, Slough

Reference

None

Amgen Ltd

Address

, Cambridge

Reference

None

Aventis Pharma ltd t/a Sanofi

Address

, Reading

Reference

None

UCB Pharma Ltd

Address

, Slough

Reference

None

Teva UK Limited

Address

, Castleford

Reference

None

Zentiva Pharma UK Ltd

Address

, London

Reference

None

CST Pharma Limited

Address

, Walsall

Reference

None

Supplier is SME?

Yes

Takeda UK Ltd

Address

, London

Reference

None

Mylan

Address

, Barnet

Reference

None

Supplier is SME?

Yes

Gilead Sciences Limited

Address

, Holborn

Reference

None

Organon Pharmaceuticals UK Ltd

Address

, London

Reference

None

Gedeon Richter UK Ltd

Address

, Maida Vale - London

Reference

None

Supplier is SME?

Yes

Sobi (Swedish Orphan Biovitrum Ltd)

Address

, Cambridgeshire

Reference

None

Supplier is SME?

Yes

About the buyer

Contact name

Giorgie Rushton

Address

2nd Floor Rutland House
Runcorn
WA7 2ES
UK

Email

giorgie.rushton2@nhs.net